Search Results - oncology

89 Results Sort By:
Advancement in Platinum Based Cancer Therapeutics
Project ID: D2013-02 Novelty: Small drug like molecules that inhibits DNA repair factors for cisplatin (and other platinum based drugs) resistance towards solid tumors, thereby increasing cisplatin cytotoxicity and efficacy. Value proposition: One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer...
Published: 1/2/2025   |   Inventor(s): Stephan Patrick, Paul Erhardt
Keywords(s): Cisplatin, Clinical Trials, DNA Repair, Ovarian Cancer, Platinum
Category(s): Oncology
S100A4 Monoclonal Antibody for Therapeutic and Diagnostic Use
Cancer metastasis are responsible for ~90% of cancer associated deaths. Recent studies suggest that immune cells play critical roles in promoting metastasis, especially myeloid cells from the bone marrow. UTHealth researchers, with researchers from The Methodist Hospital, observed a highly conserved expression of S100A4 in immune suppressive myeloid...
Published: 10/21/2024   |   Inventor(s): Zhiqiang An, Ningyan Zhang
Keywords(s):  
Category(s): Neurology/Neurosurgery, Oncology, Therapeutics
Antibodies against CD5L for therapeutic and diagnostic uses
Provided herein are anti-CD5L monoclonal antibodies. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer. UTHealth Ref. No.: 2020-0016 Inventors: Dr. Zhiqiang An and Dr. Ningyan Zhang at UTHealth; Dr. Anil Sood at UT M.D. Anderson Cancer Center Patent Status: PCT application PCT/US2021/025429...
Published: 10/21/2024   |   Inventor(s): Zhiqiang An, Ningyan Zhang, Anil Sood
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
Survivin Inhibitors for Targeted Cancer Treatment
Project ID: TECH-2024-07 Background Prostate cancer is one of the most common cancers and the second-most lethal cancer among men in the United States. While the response to standard androgen deprivation therapy (ADT) is often dramatic, most prostate cancer patients develop resistance to ADT, leading to castration-resistant prostate cancer (CRPC)....
Published: 5/21/2024   |   Inventor(s): Jian-Ting Zhang, Jasmine (Jing-Yuan) Liu, Tim (Qingbin) Cui
Keywords(s):  
Category(s): Oncology
Monoclonal Antibodies Against PCDH7 for Therapeutic and Diagnostic Use
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-associated deaths worldwide. UTHealth researchers discovered that the cell surface protein Protocadherin 7 (PCDH7) is highly expressed in NSCLC and promotes lung cancer development. Inventors at UTH in collaboration with Dr. O’Donnell’s group at UTSW have discovered a panel...
Published: 10/21/2024   |   Inventor(s): Zhiqiang An, Ningyan Zhang, Kathryn O'Donnell
Keywords(s):  
Category(s): Diagnostics, Oncology, Therapeutics, Biologics
Monoclonal antibodies against human endotrophin for therapeutic and diagnostic use.
Background Studies have shown that endotrophin, the carboxy-terminal cleavage product of the COL6α3 chain, has potent effects on transformed mammary ductal epithelial cells in rodents. It is abundantly expressed in adipose tissue and is a chemoattractant for macrophages, exerts effects on endothelial cells and enhances the progression through...
Published: 10/21/2024   |   Inventor(s): Zhiqiang An, Ningyan Zhang, Philipp Scherer
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
Monoclonal Antibodies Binding to Transferrin Receptor (TfR) for Therapeutic Protein Delivery across Blood-Brain Barrier
Blood-brain barrier (BBB) limits brain entry and is one of the major hurdles in developing antibody and protein-based therapeutics for central nervous system (CNS) diseases. UTHealth researchers identified and engineered monoclonal antibodies binding to transferrin receptor (TfR) but not affecting transferrin (Tf) binding to TfR. An engineered monovalent...
Published: 10/21/2024   |   Inventor(s): Zhiqiang An
Keywords(s):  
Category(s): Drug Delivery, Therapeutics, Neurology/Neurosurgery, Oncology, Biologics
Smart Exosomes Enable Active Pdac Targeting and Evading Mononuclear Phagocycotic System
Project ID: D2021-13 Background Patients affected by pancreatic ductal adenocarcinoma (PDAC), an aggressive type of cancer, have a 5-year survival rate of 9%, the lowest of any cancer in the US. Therapies for pancreatic cancer are largely hindered by the lack of an effective delivery system. Exosomes are emerging as promising nanocarriers for genes...
Published: 5/21/2024   |   Inventor(s): Shi-He Liu, F. Charles Brunicardi
Keywords(s):  
Category(s): Oncology
Anti-Cancer Maleimide Derivatives for Use with Immune Checkpoint Blockade
Overview We have invented a cancer treatment that consists of administering an anti-cancer maleimide derivative together with an immune checkpoint blockade. Market Opportunity Globally, colorectal cancer (CRC) ranks third in incidence and second in mortality. The U.S. Food and Drug Administration recently approved the checkpoint inhibitors nivolumab...
Published: 9/3/2024   |   Inventor(s): Wafik El-Deiry, Kelsey Huntington
Keywords(s):  
Category(s): Therapeutics, Oncology
Treating Glioblastoma, Metastatic Melanoma, and Other Tumors Involving CNS Metastases
Overview Metastasis involving the spread of systemic cancer to the brain typically results in neurologic disability and death; current treatments are largely palliative in nature. We have invented a method of treatment based on determining whether the patient has an increased level of MDM2/MDM4 genes and/or proteins and/or a decreased level of CDKN2A...
Published: 6/7/2023   |   Inventor(s): Wafik El-Deiry, Taylor Arnoff
Keywords(s):  
Category(s): Diagnostics, Therapy Targets, Oncology
1 2 3 4 5 6 7 8 9